ArticleTherapeutic advances in medical oncology2019

Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial.

Giuseppe Gullo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.